Morcellator Controversy Continues, As Bernstein Liebhard LLP Notes Nearly 87,000 Signatures on Petition to Ban Power Morcellators in Gynecological Surgery

Share Article

The number of signatures continues to grow, despite a recent decision by the FDA not to ban power morcellators.

Free Case Review
It is interesting to note that the number of signers to this petition continues to grow even though U.S. health regulators have already decided not to ban the devices.

A petition seeking a ban on the use of power morcellators ( in minimally-invasive hysterectomies and fibroid removal surgeries continues to gain signatures at a rapid pace, Bernstein Liebhard LLP reports. According to, at least 86,939 people had signed the petition as of December 26, 2014. That represents an increase of 441 signatures since November 21st, when 86,499 supporters had signed on to the campaign.*

“It is interesting to note that the number of signers to this petition continues to grow even though U.S. health regulators have already decided not to ban the devices,” says Bernstein Liebhard LLP, a nationwide law firm representing victims of defective drugs and medical devices. The Firm is currently investigating claims on behalf of women who may have experienced the spread of undiagnosed cancers due to uterine morcellation.

Power Morcellators and Cancer
Power morcellators are used during minimally-invasive gynecological procedures to cut tissue into fragments in order to facilitate its removal through a small abdominal incision. In April, the U.S. Food & Drug Administration (FDA) issued an alert announcing it was reviewing the safety of the devices, and discouraged doctors from using power morcellators due to their potential to disseminate undetected uterine cancer cells into the peritoneal cavity. This occurrence can upstage the disease to its most deadly stage, greatly reducing a woman’s chance for long-term survival.**

On November 24th, the FDA announced its long-awaited decision on the matter. While it stopped short of banning the use of power morcellators in uterine surgeries, the agency did caution against their use in the majority of women who require hysterectomies and fibroid removal surgeries. The FDA also announced that it had asked power morcellator manufacturers to add a black box warning – the strongest possible safety warning – to their labeling. The agency acted after its review suggested that the prevalence of unsuspected uterine sarcoma in patients undergoing such procedures is 1 in 352, while the prevalence of unsuspected uterine leiomyosarcoma is 1 in 498, which is higher than previously thought.

Women who were diagnosed with advanced uterine cancers following hysterectomies or fibroid removal surgeries that involved the use of a power morcellator may be entitled to compensation. To learn more about the risks associated with uterine morcellation, please visit Bernstein Liebhard LLP's website. To obtain a free consultation, please call 800-511-5092.

*,, December 26, 2014
**, FDA, April 17, 2014

About Bernstein Liebhard LLP
Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993. As a national law firm, Bernstein Liebhard LLP possesses all of the legal and financial resources required to successfully challenge billion dollar pharmaceutical and medical device companies. As a result, our attorneys and legal staff have been able to recover more than $3 billion on behalf of our clients. The Firm has been named by The National Law Journal to the Plaintiffs’ Hot List, recognizing the top plaintiffs firms in the country, for the past 12 consecutive years. Bernstein Liebhard LLP is the only firm in the country to be named to this prestigious list every year since it was first published in 2003.

Bernstein Liebhard LLP
10 East 40th Street
New York, New York 10016

ATTORNEY ADVERTISING. © 2014 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, 800-511-5092. Prior results do not guarantee or predict a similar outcome with respect to any future matter.

Contact Information:
Felecia L. Stern, Esq.
Bernstein Liebhard LLP

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Felecia L. Stern
Follow us on
Visit website